Barry S. Ticho, M.D., Ph.D., FACC

Chief Medical Officer


Barry Ticho is the chief medical officer at Stoke Therapeutics, where he is helping to lead the company’s efforts to develop first-in-class therapeutics to treat rare diseases. Prior to joining Stoke, Barry was most recently head of development of mRNA treatments for cardiovascular and metabolic diseases at Moderna Therapeutics. Before Moderna, he was head of external R&D innovation for cardiovascular and metabolic diseases at Pfizer, and before that, he was vice president of clinical development at Biogen. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago. He completed pediatrics training at Northwestern University and a cardiology fellowship at Boston Children’s Hospital. Barry has also served as a member of the clinical staff at Harvard Medical School and Massachusetts General Hospital, where he conducted laboratory research on the regulation of cardiac development.

Stoke Leaders in the News

Biotech 2050 Podcast

Stoke's Chief Medical Officer, Barry Ticho MD, PhD, shared his background in science and medical training on the Biotech2050 podcast. His unique experiences provide him with the necessary knowledge to help lead our team as we work to help people living with severe diseases.

CheckRare: What is Dravet Syndrome?

Learn more from Stoke CMO Dr. Barry Ticho about the impact of #Dravetsyndrome on people living with the disease & the need for a medicine that treats the underlying cause in this CheckRare interview.